Clinical trials
Observational Adenoma, Islet Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2017 | 2 |
| 2019 | 5 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 8 |
| Unknown status | 8 |
| Active, not recruiting | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 2 |
| University Medical Center Groningen | 2 |
| Azienda Ospedaliera Universitaria Integrata Verona | 1 |
| Changhai Hospital | 1 |
| European Institute of Oncology | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
| Francesco De Cobelli | 1 |
| Huazhong University of Science and Technology | 1 |
| IRCCS San Raffaele | 1 |
| Institut Paoli-Calmettes | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenoma, Islet Cell | 31 |
| Pancreatic Neoplasms | 7 |
| Neuroendocrine Tumors | 4 |
| Carcinoma, Renal Cell | 3 |
| Pancreatitis | 3 |
| Pancreatitis, Chronic | 3 |
| Somatostatinoma | 3 |
| Autoimmune Pancreatitis | 2 |
| Carcinoid Tumor | 2 |
| Neoplasms | 2 |
Trials
Showing 26 to 31 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.